{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-241849","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.074577+00:00","generated_at":"2026-06-10T08:45:21.473113+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pliant Therapeutics reports positive Phase 2a INTEGRIS-PSC data for bexotegrast in PSC","bullets":["Trial met primary safety endpoint; bexotegrast well tolerated with 94% completing 12 weeks, no drug-related SAEs.","Exploratory efficacy: significant reduction in ELF score and PRO-C3 at 160 mg vs placebo at Week 12.","Dose-dependent trend in ALP reduction; MRI imaging suggests improved hepatocyte function and bile flow.","High-dose 320 mg interim data expected Q1 2024; full 24-week data mid-2024.","Company to host webcast today at 8:00 AM ET to discuss results."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-241849","json":"https://secwatch.observer/filing/0001193125-23-241849.json","markdown":"https://secwatch.observer/filing/0001193125-23-241849.md","text":"https://secwatch.observer/filing/0001193125-23-241849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000119312523241849/0001193125-23-241849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000119312523241849/d473253d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:45:21.473113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}